ADU-1604
Advanced Melanoma
Phase 1Active
Key Facts
About Sairopa
Sairopa is a private, clinical-stage biotech company developing next-generation immunotherapies to address the limitations of current checkpoint inhibitors, which benefit only about 30% of cancer patients. Its core assets include ADU-1805 (anti-SIRPalpha) and ADU-1604 (anti-CTLA-4), acquired from Chinook Therapeutics and originally derived from the B-Select antibody platform used for Keytruda. The company is led by a small, experienced team with strong ties to Dutch life sciences investment firm Van Herk Investments and is currently advancing its lead candidate, ADU-1604, in Phase 1 clinical trials for advanced melanoma.
View full company profileTherapeutic Areas
Other Advanced Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| RP1 | Replimune | Phase 2/3 |
| LN-144 (via Iovance) | OmniAb | BLA Submitted |